Document:

Exhibit 10.33

 

CONFIDENTIAL

EXECUTION
VERSION

 

LICENSE AGREEMENT

 

THIS LICENSE
AGREEMENT (this “Agreement”) is made and entered into as of the “Effective Date” (defined
below) by and between Healeon Medical, Inc., a corporation organized under the laws of the State of Delaware, having a place
of business at 1111 Rancho Conejo Blvd #204, Newbury Park, CA 91320 and its wholly-owned subsidiary Healeon Medical Ltd., an
entity organized under the laws of Israel and having its principle place of business in Israel, (“Healeon”) on
the one hand and Suneva Medical, Inc., a corporation organized under the laws of the State of Delaware, having a place of
business at 5870 Pacific Center Boulevard, San Diego, California 92121 (“Suneva”) on the other (each individually
each a “Party” and jointly the “Parties”).

 

WHEREAS,
Healeon is the sole owner of the Licensed Intellectual Property (as defined below);

 

WHEREAS,
Healeon is the developer and owner of certain platelet rich plasma preparation (“PRP”) and fat transfer products as defined
below;

 

WHEREAS,
Healeon and Suneva, as a condition to entering into this Agreement, are also entering into a Supply Agreement (with associated Quality
Agreement) dated as of the Effective Date hereof (the “Supply Agreement”); and

 

WHEREAS,
Suneva desires to obtain, and Healeon wishes to grant to Suneva, an exclusive, worldwide, transferable license to the Licensed Intellectual
Property, Products, and certain future products to be developed in the Field of Use and in the Territory (each as defined below), subject
to and in accordance with the terms and conditions of this Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties, and subject
to the terms and conditions herein, and intending to be legally bound (as of the Effective Date), the parties agree as follows:

 

ARTICLE 1

Definitions

 

For
the purposes of this Agreement, the following capitalized words and phrases shall have the following meanings:

 

1.1   “Act”
means the United States Federal Food, Drug, and Cosmetic Act, as amended to date and as may be further amended from time to time during
the Term (as defined below), and the regulations promulgated with respect thereto.

 

    - 1 -

     

    

 

1.2   “Affiliate” means, with respect to any Person, any other
Person which directly or indirectly controls, is controlled by, or is under common control with, such Person, only for so long as such
control continues to exist. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls,
at least fifty percent (50%) of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses
the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever.

 

1.3
“Applicable Law” means all laws, rules, regulations and guidelines
within the Territory (including, but not limited to, the Act and all regulations promulgated thereunder), as existing as of the
Effective Date and as may be amended from time to time thereafter, that apply to the import, export, research and development,
manufacture, marketing, distribution and/or sale of Products in the Territory or the performance of either Party’s obligations under
this Agreement, in each case to the extent applicable and relevant to such Party.

 

1.3.1   “Effective
Date” means the date of a Notice sent by Suneva to Healeon pursuant to Section
13.8 indicating that: (i) Suneva has completed due diligence to its satisfaction; (ii) Suneva agrees to release its signature pages to
this License Agreement and to the Supply Agreement from escrow; and (iii) Suneva agrees to be legally bound by this License Agreement
and the Supply Agreement. Suneva shall have until November 15, 2018 to conduct such due diligence. For avoidance of doubt, and notwithstanding
any other provision of this License Agreement or of the Supply Agreement, neither party has or shall have any legal obligation to the
other (except to conduct commercially reasonable due diligence in good faith up and until November 15, 2018) unless and until Suneva in
its sole discretion elects to deliver such Notice.

 

1.4   “Encumbrance”
means any lien, license, security interest, pledge, option or other encumbrance,
restriction or limitation of any kind whatsoever that would (if ever enforced or exercised) prevent Suneva from (or otherwise adversely
impact Suneva in) fully exercising or otherwise exploiting the rights granted under Section 2.1 and elsewhere in this Agreement.

 

 1.5 “PRP” means platelet rich plasma, platelet rich fibrin, platelet rich fibrin matrix

 

1.6 “Change
of Control” means a change in the ownership of Healeon (as defined by
either the acquisition or control of a majority interest in the equity of Healeon or control of a majority of the Healeon Board of
Directors by any company manufacturing or marketing medical aesthetics products or in connection with an initial public offering by
Healeon or a reverse merger transaction Property pursuant to which Healeon becomes a public reporting company)
or a change in the ownership or control of the Licensed Intellectual or Products. 

 

1.7   “Control”
means with respect to any item of or right under any Patents, Technical Information,
or Trademarks or any other Intellectual Property Rights, the possession of (whether by ownership or license, other than pursuant to this
Agreement) or the ability of a Party or, if applicable, any of its Affiliates to grant a license or sublicense of such items or right
as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such
Party would be required hereunder to grant the other Party such license or sublicense and without payment of additional consideration
to such Third Party.

 

    - 2 -

     

    

 

1.8   “Cover”
or “Covering” means, (i) with respect to a Patent, that at least one Valid
Claim of such Patent would be infringed by the product, method, use, or device, as applicable, and (ii) with respect to any other Intellectual
Property Right, that the product, method, use or device would infringe or misappropriate such rights unless a license were granted.

 

 1.9 “Dual Chamber Syringe” means any syringe having at least two chambers and covered by at least one Valid Claim including, for example, the device specified in Schedule C.

 

1.10   “FDA”
means the United States Food and Drug Administration and any successor entity thereto.

 

1.11   “Field
of Use” means PRP and fat transfer performed by physicians and medi-spas for
aesthetic indications. Only medical spas with an associated medical license number will be within the Field of Use.

 

 1.12 “Finished Product” means a saleable Product in final trade dress and packaging.

 

1.13   “GAAP”
means U.S. generally accepted accounting principles as in effect at the relevant time or for the relevant period applied on a consistent
basis during the period involved.

 

1.14   “Healeon
Improvement” means any Improvement with respect to which employees, agents and/or
subcontractors of Healeon are sole inventors. Inventorship for Healeon Improvements shall be determined in accordance with the patent
laws of the United States (Title 35, United States Code).

 

1.15   “Improvement”
means any adaptation, change, redesign, modification, invention, discovery, enhancement
or development conceived, reduced to practice, developed or made after the Effective Date and requiring the practice of an invention claimed
in the Patent Rights.

 

1.16
“Intellectual Property Rights” means any and all patent rights,
copyright rights, trade secret rights, sui generis database rights and all other intellectual and industrial property rights
of any sort throughout the world (including, but not limited to, any application therefore) whether now known or hereafter
existing.

 

1.17   “Joint
Improvement” means an Improvement with respect to which employees and/or agents
of both Healeon and Suneva are joint inventors in the course of performing any of their respective activities under this Agreement or
under the Supply Agreement, regardless of whether any Third Parties are also joint inventors, including, without limitation, all Intellectual
Property· Rights therein. Inventorship for Joint Improvements shall be determined in accordance with the patent laws of the United
States (Title 35, United States Code).

 

 1.18 “Joint Patent” means any Patent Covering a Joint Improvement.

 

1.19   “Licensed
Intellectual Property” means, collectively: (i) the Patent Rights, (ii) the
Technical Information, (iii) Healeon Improvements, (iv) Suneva Improvements, and (v) any Joint Improvements and Joint Patents.

 

    - 3 -

     

    

 

1.20   “Patent”
means any patent or patent application, including, without limitation, any United States provisional application, any United States non-provisional
application, and any continuation, continuation-in-part, divisional, registration, confirmation, revalidation, reissue, substitution,
reexamination, renewal, PCT application, patent term extension, SPC, and utility model, as well as all related extensions or restorations
of terms thereof.

 

1.21   “Patent
Rights” means: (i) all Patents set forth on Schedule A; (ii) any other Patents (excluding the Joint Patents), whether
existing as of the Effective Date or arising thereafter, that at any time during the Term are owned or otherwise Controlled by Healeon
and that have at least one Valid Claim Covering the composition of matter, method, manufacture, formulation, sale or use of any Product
in the Field of Use in the Territory; and (iii) any and all Patents and other rights issuing from, or filed subsequent to the Effective
Date of this Agreement and based on or claiming priority to or from, any of the Patents described in the preceding clause (i) of this
definition, including, but not limited to, any Patents resulting from any of the foregoing.

 

 1.22 “Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint venture, non-profit organization, pool, syndicate, sole proprietorship, unincorporated organization, university, governmental authority or any other form of entity not specifically listed herein.

 

1.23   “Product(s)”
means the current and all future models/versions of (a) Healeon’s proprietary Dual Chamber Syringe and (b) Healeon’s PRP Gel Tube, each
as specified in Schedule C.

 

1.24   “PRP
Gel Tube” means a tube (e.g., a PET tube) designed for the preparation of PRP, containing a thixotropic gel, and having a maximum
working volume of 12 ml of whole blood.

 

1.25 “Regulatory
Authority” means any administrative agency responsible for the regulation of cosmetic or pharmaceutical products intended for
human use, including, but not limited to, the FDA, and any other applicable administrative agency in the Territory having the aforementioned
responsibilities and any successor entities thereto.

 

1.26 “Regulatory Filings and Approvals”
means any and all permits, licenses, approvals, clearances, designations and authorizations required by any Regulatory Authority
as a prerequisite to the development, manufacturing, packaging, marketing, selling and/or use of a Product in the Field of Use in any
jurisdiction in the Territory, or otherwise issued by any Regulatory Authority with respect to any Product in the Field of Use in any
jurisdiction in the Territory, as well as any _ _ applications for any of the foregoing filed with any Regulatory Authority. 

 

 1.27 “Sublicensee” means any Third Party or Affiliate of Suneva that has entered into an agreement with Suneva sublicensing to such Third Party or Affiliate pursuant to Section 2.2 any of the rights granted to Suneva by Healeon pursuant to Section 2.1. For clarity, “Sublicensee” includes, but is not limited to, any Third Party that is sublicensed or otherwise authorized by Suneva to import, export, offer for sale, sell or otherwise promote, market and distribute Products in the Territory, but which has no right to make or have made any Products, such as distributors or value added resellers.

 

    - 4 -

     

    

 

1.28   “Technical
Information” means (i) any technical, scientific and other data, information and know-how (including, but not limited to,
any biological, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, pre-clinical, clinical, safety,
manufacturing and quality control data and information, and further including, but not limited to, study designs and protocols,
assays and biological methodology) that (a) is described on Schedule B, (b) was or is used, created or developed either by or
on behalf of Healeon, and relates directly to a Product in the Field of Use or (c) is at any time during the Term owned or otherwise
Controlled by Healeon, whether existing as of the Effective Date or arising thereafter, and is necessary for the development, use or
manufacture of Products for the Field of Use and (ii) any and all Intellectual Property Rights embodied in or associated with any of
the foregoing; provided, however, that notwithstanding anything to the contrary, the Technical Information shall not include any
Joint Patents or Joint Improvements.

 

 1.29 “Territory” means the United States of America, Mexico, Canada, South Korea and China (including Hong Kong and Macau).

 

1.30   “Third
Party” means any Person other than Healeon, Suneva and their respective Affiliates.

 

1.31   “Trademark”
means any rights to: (i) any future or existing Suneva owned trademark(s) that may be used in the commercialization of the Product;
(ii) any and all trademarks, service marks, trade names, logos and trade dress specific to or typically used by Healeon with the Products;
and (iii) any and all applications, registrations, common law rights and other rights with respect to any of the foregoing.

 

1.32   “Suneva
Improvement” means any Improvement with respect to which employees, agents and/or subcontractors ofSuneva are sole inventors.
Inventorship for Suneva Improvements shall be determined in accordance with the patent laws of the United States (Title 35, United States
Code).

 

1.33 “Valid
Claim” means a claim pending (and not abandoned by Healeon or its licensor(s) in a Patent application included within the
Patent Rights, or an issued and unexpired claim in a Patent included within the Patent Rights, which claim, in each case (i) has not
been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent
jurisdiction (which decision is not appealable or has not been appealed within the time allowed for appeal), and which claim has not
been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise and
(ii) would but for the license granted hereunder, be infringed by the manufacturing, use, import, export,
development, distribution, marketing, promotion, offer to sell and sale of a Product in Use in the Territory.

 

ARTICLE 2

License Grant

 

 2.1 Grant of License

 

 2.1.1 License Grant

 

		2.1.1.1.	Dual Chamber Syringe: During the Term and subject to Suneva’s
compliance with the terms and conditions of this Agreement, Healeon, on behalf of itself and its Affiliates, hereby grants to Suneva
an exclusive (even as to Healeon and its Affiliates), transferable (to the extent permitted under Section 13.2 below) license,
with the right to grant sublicenses in accordance with Section 2.2, under the Licensed Intellectual Property, solely in the Field
of Use and within the Territory, to make, have made, use, import and export, develop, register, warehouse, distribute, market, promote,
offer to sell, sell and otherwise commercially exploit the Dual Chamber Syringe.

 

    - 5 -

     

    

 

		2.1.1.2	PRP Gel Tube: During the Term and subject to Suneva’s
compliance with the terms and conditions of this Agreement, Healeon, on behalf or itself and its Affiliates, hereby grants to Suneva
a non-exclusive, transferable (to the extent permitted under Section 13.2 below) license, with the right to grant sublicense in
accordance with Section 2.2, under the Licensed Intellectual Property, solely in the Field of Use and within the Territory, to
make, have made, use, import and export, develop, register, warehouse, distribute, market, promote, offer to sell, sell and otherwise
commercially exploit the PRP Gel Tube. For the avoidance of doubt, Healeon and its Affiliates retain the right to sell the PRP Gel Tube
and similar products, including those with the same or different working volumes, within and outside the Territory and within and outside
the Field of Use.

 

 2.1.2 No Manufacture Except Following a Triggering Event

 

Notwithstanding
the foregoing license to make and have made, Suneva shall not manufacture, make or have made the Products other than in accordance with
the Supply Agreement in the event of a Triggering Event as defined therein.

 

 2.1.3 Reserved Right

 

Notwithstanding the foregoing exclusive license grant, Healeon reserves and retains the right to perform directly or
indirectly, any and all research and development activities concerning Products as Healeon deems appropriate. Further, the exclusivity
described above in Section 2.1 shall not preclude Healeon from performing its obligations under the Supply Agreement.

 

 2.2 Sublicensing

 

Suneva may
sublicense all or any portion of its rights set forth in Section 2.1 above to Sublicensees with or without the further right to·sublicense
under the following conditions:

 

		2.2.1.	Suneva shall notify Healeon in advance and in writing of
any potential Sublicensees;

 

		2.2.2.	Healeon shall approve in advance all Sublicensees and sublicenses,
wherein such approval shall not be unreasonably withheld;

 

		2.2.3.	all sublicenses must be in writing and signed by both applicable
parties, enforceable according to its terms;

  

    - 6 -

     

    

 

		2.2.4.	no sublicense will grant, or purport to grant, any broader
rights than those set forth in Section 2.1; and

 

		2.2.5.	Sublicensees agree in writing to:

 

		2.2.5.1.	acknowledge that Healeon may cancel any sublicense for cause
including, but not limited to, poor Product quality or marketing practices of the Sublicensee, and

 

		2.2.5.2.	acknowledge that termination of this License Grant set forth
in Section 2.1 causes (a) termination the sublicense or (b) the conversion to a license directly between Healeon and the Sublicensee
upon mutual agreement between Healeon and the Sublicensee.

 

ARTICLE 3

Regulatory Matters

 

 3.1 Ownership and Maintenance of Regulatory Filings and Approvals

 

As between the
parties, Healeon shall solely own any Regulatory Filings and Approvals in the United States that are either: (i) pending or in
effect as of the Effective Date or (ii) made by or on behalf of it, or are obtained by or on behalf of it, following the Effective
Date. As to non-US jurisdictions (present or future) Suneva, in its sole discretion and acting directly or through its sublicensee
or agent, will be responsible for the filing and maintenance of any non-U.S. Regulatory Filings and Approvals deemed necessary for
the marketing of the Products in such any jurisdiction(s) within the Field of Use. Healeon shall promptly notify Suneva in writing
of any correspondence received from any Regulatory Authority relating to any Product with respect to the manufacture of Product,
Field of Use and the Territory, or Regulatory Filings and Approvals relating to any Product with respect to the Field of Use and the
Territory, and shall provide Suneva with copies of any such correspondence. Healeon will provide Suneva with reasonable assistance,
at no charge to Suneva, with respect to Regulatory Filings and Approvals outside the United States that are either: (i) pending or
in effect as of the Effective Date or (ii) made by or on behalf of Suneva, or are obtained by or on behalf of Suneva, following the
Effective Date. Healeon represents and warrants that it shall obtain U.S. Regulatory Approval for each and all of the Products on or
before December 31, 2019 and agrees that if it fails to do so by said date, it will refund certain payments to Suneva as
provided in Section 6,1.

 

ARTICLE 4

Delivery of Technical Information; Assistance; Development and Marketing; Non-Compete

 

 4.1 Delivery of Technical Information

 

Promptly after
the Effective Date, and from time to time thereafter as may be reasonably requested by Suneva, Healeon shall deliver to Suneva, at
no charge to Suneva, copies of all Technical Information reasonably in Healeon’s possession as of the Effective Date or, if
applicable, at the time of any subsequent request. Healeon represents and warrants that Suneva has a complete, current
written description of the Products and the process needed to manufacture same. Healeon will update this information to include any
subsequent improvements, adjustments or refinements manufacturing process.

 

    - 7 -

     

    

 

 4.2 Development and Commercialization

 

4.2.1   Subject
to Section 4.2.3 and Healeon’s performance of its obligations under the Supply Agreement, and further subject to any required Regulatory
Authority approvals, Suneva shall use commercially reasonable efforts, itself and/or through the activities of Sublicensees, to commercialize
Products in the Territory.

 

4.2.2   Subject
to this Section 4.2, Suneva shall have sole discretion over all marketing, pricing, promotion, strategy, reimbursement, branding,
distribution and sales issues relating to any Product in the Field of Use in the Territory.

 

4.2.3 The parties
acknowledge and agree that, notwithstanding anything to the contrary: (i) the obligations of Suneva with respect to the Products
under this Section 4.2 are expressly conditioned upon, among other things, the continuing absence of any material adverse
condition or event beyond Suneva’s reasonable control relating to the safety, efficacy or commercial viability of the Product,
and the obligations of Suneva under this Section 4.2 shall be delayed or suspended so long as any such material adverse
condition or event exists and (ii) in addition, Suneva shall not be in breach of this Agreement for any failure to meet any of its
obligations under this Section 4.2, to the extent such failure is attributable to any delay or other act or omission of
Healeon or any Regulatory Authority, or any other cause outside the reasonable control of Suneva.

 

 4.3 Supply Agreement

 

 4.3.1 Manufacturer

 

The
parties acknowledge that pursuant to the Supply Agreement, Healeon has agreed to manufacture the Products for Suneva. The parties acknowledge
that Suneva reserves the right to transfer any or all of the services provided by Healeon under the Supply Agreement to an Alternate Manufacturing
Facility only under the circumstances set forth in and subject to the Supply Agreement.

 

 4.4 Non-Diversion: Healeon.

 

Except as otherwise
provided herein, during the Term, neither Healeon nor its Affiliates will, without the written consent of Suneva, directly or
indirectly manufacture, sell, license, distribute, supply, commercially exploit, make available, or otherwise directly or indirectly
provide or divert any Product (or grant any rights in relation to any of the foregoing) for, or to any Person other than Suneva or
its Affiliates in the Territory within the Field of Use (a “Direct Diversion”). In addition, Healeon shall use
commercially reasonable efforts to ensure that none of its distributors nor its licensees will engage in any activities that if
taken by Healeon would be a Direct Diversion (an “Indirect Diversion” and together with a Direct Diversion, a
“Healeon Diversion”). Such commercially reasonable efforts shall include (i) requiring all future licensees and
distributors to agree to negative covenants concerning Indirect Diversions, and (ii) Healeon’s reasonable enforcement of such
covenants.

 

    - 8 -

     

    

 

In
the event that Healeon becomes aware of a material Healeon Diversion, Healeon shall promptly provide Suneva with written notice of such
Healeon Diversion. Such notice shall describe the facts concerning such Healeon Diversion to the best of Healeon’s knowledge, and Healeon’s
strategy to prevent the continuation of such Healeon Diversion. In the case of a material Direct Diversion, Healeon shall take such actions
as are necessary to cause the termination of such Direct Diversion. In the case of an Indirect Diversion, shall use commercially reasonable
efforts to cause the termination of such Indirect Diversion. If, (i) in the case of a Direct Diversion, Healeon shall fail to terminate
such Direct Diversion or (ii) in the case of an Indirect Diversion, Healeon shall (a) fail to use commercially reasonable efforts
to cause the termination of such Indirect Diversion or (b) despite the use of commercially reasonable efforts such Indirect Diversion
shall continue for a period of one hundred eighty (180) days thereafter, Healeon shall compensate Suneva for any losses incurred as a
result of such Healeon Diversion incurred on and after the date which is one hundred and eighty (180) days following Healeon obtaining
actual knowledge of such Healeon Diversion. The parties hereto agree that a reasonable estimate of Suneva’s losses under such a circumstance
shall be two (2) times Suneva’s lost gross profit on the Product that is the subject of such Healeon Diversion. As such the parties hereto
agree to such amount as liquidated damages, and not as a penalty. For the avoidance of doubt, to the extent that there are multiple Healeon
Diversions, each Healeon Diversion shall be treated as a separate and independent event hereunder.

 

 4.5 Non-Diversion: Suneva.

 

During
the Term, neither Suneva nor its Affiliates will, without the written consent of Healeon, directly or indirectly manufacture, sell, license,
distribute, supply, commercially exploit, make available, or otherwise directly or indirectly provide or divert any amounts of Product
(or grant any rights in relation to any of the foregoing) for, or to any Person other than Healeon or its Affiliates outside of the Territory
and the Field of Use (a “Direct Diversion”). In addition, Suneva shall use commercially reasonable efforts to ensure that none
of its distributors nor its licensees will engage in any activities that if taken by Suneva would be a Direct Diversion (an “Indirect
Diversion” and together with a Direct Diversion, a “Suneva Diversion”). Such commercially reasonable efforts shall include
(i) requiring all future licensees and distributors to agree to negative
covenants concerning Indirect Diversions, and (ii) Suneva’s reasonable enforcement of such covenants.

 

In
the event that Suneva_becomes aware of a material Suneva Diversion, provide Healeon with written notice of such Suneva Diversion.
Such notice shall describe the facts concerning such Suneva Diversion to the best of Suneva’s knowledge, and
Suneva’s strategy to prevent the continuation of such Suneva Diversion. In the case of a material Direct Diversion, Suneva
shall take such actions as are necessary to cause the termination of such Direct Diversion. In the case of an Indirect Diversion,
shall use commercially reasonable efforts to cause the termination of such Indirect Diversion. If, (i) in the case of a Direct
Diversion, Suneva shall fail to terminate such Direct Diversion or (ii) in the case of an Indirect Diversion, Suneva shall (a) fail
to use commercially reasonable efforts to cause the termination of such Indirect Diversion or (b)
despite the use of commercially reasonable efforts such Indirect Diversion shall continue for a period of one hundred eighty (180)
days thereafter, Suneva shall compensate Healeon for any losses incurred as a result of such Suneva Diversion incurred on and
after the date which is one hundred and eighty (180) days following Suneva obtaining actual knowledge of such Suneva Diversion. The
parties hereto agree that a reasonable estimate of Healeon’s losses under such a circumstance shall be two (2) times
Healeon’s lost gross profit on the Product that is the subject of such Suneva Diversion. As such the parties hereto agree to
such amount as liquidated damages, and not as a penalty. For the avoidance of doubt, to the extent that there are multiple Suneva
Diversions, each Suneva Diversion shall be treated as a separate and independent event hereunder.

 

    - 9 -

     

    

 

 4.6 Non-Compete with Respect to Dual Chamber Syringe

 

For
so long as Suneva, its Affiliates or any Sublicensee has rights to the Licensed Intellectual Property, neither Healeon nor any of its
Affiliates shall develop, manufacture, market or sell (or license or assist any Third Party to develop, manufacture, market or sell) in
the Field of Use in the Territory the Dual Chamber Syringe or another syringe product with similar operating features covered by at least
one Valid Claim including, for example, the device specified in Schedule C, for the preparation of PRP blood components except
as necessary to perform Healeon’s obligations under this Agreement and the Supply Agreement. For avoidance of doubt, Healeon and its Affiliates
maintain the right to sell the PRP Gel Tube throughout the world in any field of use.

 

ARTICLES

Intellectual Property

 

 5.1 Patent Prosecution

 

At all
times, Healeon or its designee will have sole control over the filing, prosecution, maintenance, and management of any and all issued
patents and pending and future patent applications encompassing the Patent Rights and Joint Intellectual Property. Healeon will select
all outside or in-house counsel for prosecution of the Patent Rights and such counsel will represent Healeon in all such prosecution.
Healeon will keep Suneva fully informed of all prosecution related actions and will consider any comments or suggestions made by Suneva
on those actions. Each Party will promptly inform the other Party as to all matters that come to its attention that may affect the preparation,
filing, prosecution, or maintenance of the Patent Rights.

 

 5.2 Joint Intellectual Property

 

Healeon shall own,
and Suneva shall assign or have assigned all right, title and interest in any Joint Improvements and any Joint Patents. All Joint
Improvements and/or Joint Patents shall be and hereby are included in Licensed Intellectual Property and subject to the License
Grant set forth in Section 2.1 and the other obligations of this Agreement. For the avoidance of doubt, nothing in this
Section 5.2 shall sever to expand or otherwise alter the scope and definition of the Territory and the Field of Use.

 

 5.3 Patent Fee Reimbursement

 

Healeon shall pay all fees
and costs associated with the Licensed Intellectual Property, including for any Joint Patents. Suneva shall pay all fees and costs associated
with Suneva Improvements.

 

    - 10 -

     

    

 

ARTICLE
6

Financial Terms

 

 6.1 Licensee Fee

 

Suneva agrees to pay Healeon a
Licensee Fee of seven-hundred and fifty thousand dollars ($750,000) as follows: (1) within five (5) days of the Effective Date a
$150,000 initial payment; (2) on or before the 10th of each month beginning with the month following the Effective Date,
twelve payments of $50,000. Healeon hereby grants to Suneva, effective upon payment of the initial $150,000 payment, a security
interest in favor of Suneva on all Patent Rights owned or controlled by Healeon and agrees to cooperate in Suneva’s efforts to
perfect such security interest. Should Healeon fail to obtain U.S. Regulatory Approval for each and all of the Products on or before
December 31, 2019, then it shall refund $300,000 (six months oflicense payments) to Suneva on or before March 31, 2020 and such
refund shall be Suneva’s exclusive remedy for such breach.

 

 6.2 Manufacturing Fees & Minimum Annual Purchase Obligation

 

Shall be paid as specified in the Supply Agreement.

 

 6.3 Form of Payment; Late Payments; Disputed Payments

 

Unless
otherwise agreed to by the parties, all payments under this Agreement shall be paid in United States Dollars. If either Party fails to
pay any amount due under this Agreement by the applicable due date, without limiting any other remedies that may then be available to
the Party (including, without limitation, termination for material breach pursuant to Section 10.2), said Party will have the right
to assess late charges in an amount equal to the lesser of one-percent (1.0%) per month or the maximum amount allowed under Applicable
Law, whichever is lower. Notwithstanding the foregoing, late charges shall not apply in respect of amounts that either Party disputes
in good faith.

 

ARTICLE 7

Enforcement of and Challenges
to Licensed Intellectual Property

 

 7.1 Infringements

 

7.1.1 Notice of Potential Infringement.

 

During
the Term, if either Party learns of any potential infringement, unauthorized use or misappropriation, or claim of ownership by a Third
Party with respect to the Licensed Intellectual Property in connection with any Product within or outside of the Territory for any use
(each, a “Potential Infringement”), such Party shall promptly notify the other Party in writing, and shall promptly provide
such other Party with available evidence of such Potential Infringement.

 

 7.1.2 Prosecution of Potential Infringements.

 

Healeon shall
have the first right (but not the obligation) to initiate legal action to enforce all Licensed Intellectual Property, including
Joint Patents, against infringement and to protect the same from misappropriation,
or to defend any declaratory judgment or inter parties review actions (or foreign equivalents thereof) relating thereto, at
its sole expense. In the event that Healeon fails to initiate or defend such action within thirty (30) days after being first
notified of such infringement or misappropriation, Suneva shall have the right to do so for infringements within the Field of Use
and the Territory at its sole expense and using counsel of its choice.

 

    - 11 -

     

    

 

 7.1.3 Cooperation.

 

If one
Party exercises its right to initiate or defend legal action against a Third Party as set forth in Section 7.1.2 above, such initiating/defending
Party shall keep the other Party reasonably and regularly informed of the status and progress of the action. The non-initiating/non-defending
Party agrees to be joined as a Party plaintiff where necessary for purposes of legal standing and to give the initiating/defending Party
reasonable assistance and authority to file and prosecute the suit. In such case, the costs and expenses of the non-initiating/non-defending
Party shall be borne by the initiating/defending Party, and the initiating/defending Party shall indemnify the non-initiating/non-defending
Party against any claims, suits, losses, or liabilities incurred as a result of being joined as plaintiff, except to the extent arising
from the negligence or willful misconduct of the non-initiating/non-defending Party. In any event, the non-initiating/non-defending Party
shall have the right to be represented in the action by counsel of its choice and at its own expense. Any damages or other monetary awards
recovered in the action shall be used first to reimburse the Parties; documented out-of-pocket legal expenses related to the proceedings,
and then any remaining damages or other monetary awards shall be retained by the initiating/defending Party. In the event that the Parties
agree to share the cost of the action as part of a cost-sharing arrangement, such damages or other monetary awards shall be shared by
the Parties in proportion to their relative contributions to the total costs and expenses of the action, or as otherwise agreed by the
Parties in writing. A settlement or consent judgment or other voluntary final disposition of a suit under this Section 7.1.3 may
not be entered into without the consent of both Parties, which shall not be unreasonably withheld, conditioned or delayed.

 

ARTICLES 

Term and Termination

 

 8.1 Term

 

This Agreement shall
become effective on the Effective Date and, unless and until terminated pursuant to Section
8.2, Section 8.3, Section 8.4 or Section 8.5, shall continue in effect until the later
of five (5) years from the Effective Date (the “Initial Term”). Thereafter, this Agreement
will automatically renew, unless and until terminated by Suneva at will on no less than 6 months’ Notice to Healeon
or pursuant to Section 8.2, Section 8.3,
Section 8.4 or Section 8.5, for up to two successive 5-year periods each of which shall be known as a “Renewal
Term” (the Initial Term and all subsequent Renewal Terms shall be known as the “Term”).

 

 8.2 Termination for Material Breach

 

Upon
any material breach of this Agreement by a Party, including, without limitation, failure of a Party to pay any amounts due to the
other Party or to supply Products in accordance with the terms of the License or Supply Agreement, the other Party shall have the
right to terminate this Agreement by giving sixty (60) days prior, written notice to the breaching Party; provided,
however, that this Agreement shall not terminate if the breaching Party has cured such breach by the end of such sixty (60) day
period. Notwithstanding anything herein to the contrary, if the nature of the breach is such that additional time is reasonably
needed for the breaching Party to cure such breach, and the breaching Party has during such sixty (60) day period commenced good
faith and diligent efforts to cure such breach, then the other Party shall provide the breaching Party with additional time beyond
such sixty (60) day period as reasonably necessary for the breaching Party to cure such breach (but in any event, not more than four
(4) months after the date of the breach notice), provided that the breaching Party continues to act in good faith and diligently to
cure such breach during any such extension period. Notwithstanding the foregoing, however, in the event of a breach of
Healeon’s obligation to obtain Regulatory Approval for the Products on or before as the date specified in Section 3.1, Suneva
shall be entitled to Terminate this Agreement and as an exclusive remedy-shall be entitled to an immediate refund of $300,000 as set
forth in Section 6.1.

 

 8.3 Termination for Challenges to Patent Rights

 

Healeon
shall have the right to terminate this Agreement in its entirety, immediately upon the issuance of written notice to Suneva, if at any
time Suneva or any of its Affiliates or Sublicensees challenges the validity, enforceability or scope of any of the Patent Rights in any
court or before any governmental authority with authority to determine the validity, enforceability or scope of such Patent Rights, or
cause or request, without the prior written approval of Healeon, a review by any such court or governmental authority of the same.

 

    - 12 -

     

    

 

 8.4 Termination for Bankruptcy or Insolvency

 

Either
Party hereto shall have the right to terminate this Agreement immediately by written notice to the other Party (i) if the other Party
is declared insolvent or bankrupt by a court of competent jurisdiction, (ii) if a voluntary or involuntary petition in bankruptcy is filed
in any court of competent jurisdiction against the other Party and such petition is not dismissed within ninety (90) days after filing
or (iii) if the other Party shall make or execute an assignment of substantially all of its assets for the benefit of creditors. Each
of the events described in this Section 8.4 shall be known as an “Insolvency Event.”

 

 8.5 Termination for Convenience by Suneva

 

Suneva shall have
the right at any time to terminate this Agreement in its entirety, for convenience, by giving one (1) year’s notice
thereof in writing to Healeon.

 

 8.6 Consequences of Termination

 

 8.6.1 License and Assignment

 

Upon expiration or
non-renewal of the Term pursuant to Section 8.1, or any termination of this Agreement by either Party for any reason or pursuant
to any provision of this Agreement, the license granted to Suneva under Section 2.1.1 shall terminate, subject to Section 8.6.2
below, and all other rights and licenses granted to Suneva herein shall terminate and revert to Healeon on termination.

 

 8.6.2 Sublicenses

 

Notwithstanding
anything to the contrary, upon any termination of this Agreement by either Party, any sublicenses of the Licensed Intellectual
Property under each agreement pursuant to which such a sublicense was granted under this Agreement to a Sublicensee shall, to the
extent not imposing obligations on Healeon in excess of or materially different from those contained herein and to the extent
benefitting and protecting Healeon in substantially and materially the same manner contained herein, at the election of Healeon,
either: (i) be terminated automatically once Suneva notifies the applicable Sublicensee that it is exercising any termination right
provided for in the applicable sublicense agreement; or (ii) survive such termination and be automatically assigned to Healeon in
order to provide for the applicable Sublicensee’s continued enjoyment of their rights under such sublicense agreement; provided that
the applicable Sublicensee is not in breach or default of any terms of their sublicense agreement or of this Agreement as of the
date Healeon’s notice of election is received by Suneva.. Healeon shall notify Suneva of its election within ten (10) business days
following the effective date of termination of this Agreement. Failure to provide such notice to Suneva by 5:00 p.m. PST/PDT on the
last day of the ten (10) business day period will result in the automatic termination of all of Suneva’s sublicenses granted
hereunder at such time.

 

 8.6.3 Inventory

 

Notwithstanding anything to
the contrary, for one hundred eighty (180) days following the effective date of any termination of this Agreement (the “Sell-Off
Period”), Suneva and any sublicensees shall have the right, but not the obligation, to sell-off any excess Product that was manufactured
and packaged or on order prior to the effective date of termination, subject to its compliance with the terms of this Agreement applicable
to any such sales made during that period.

 

 8.6.4 Confidential Information

 

Except as otherwise
provided herein, upon termination of this Agreement, all remaining records and materials in a Party’s possession or control containing
the other Party’s Confidential Information and to which the former Party does not retain rights hereunder, shall promptly be returned
or destroyed at the request of the disclosing Party. Notwithstanding the foregoing, one copy of such records may be retained by legal
counsel for the former Party solely for archival purposes,

 8.7 Survival

 

The
following provisions shall survive any termination or expiration of this Agreement: Article 1 (“Definitions”),
Article 5 (“Intellectual Property”), Section
8.6 (“Consequences of Termination”), this Section 8.7
(“Survival”), Article 9 (“Representations
and Warranties”), Article 10 (“Limitation of Liability”),
Article 11 (“Indemnification”), Article
12 (“Confidentiality”) and Article 13 (“General
Provisions”).

 

    - 13 -

     

    

 

8.8 Remedies

 

Neither
Party shall incur any liability whatsoever for any damage, loss or expense of any kind suffered or incurred by the other (or for any compensation
to the other) arising from or incident to any termination of this Agreement which complies with the terms of this Agreement whether or
not such Party is aware of any such damage, loss or expense. Termination is not the sole remedy under this Agreement and, whether or not
termination is effected, all other remedies will remain available except as expressly agreed to otherwise herein.

 

ARTICLE 9

Representations and Warranties

 

 9.1 Mutual Representations and Warranties

 

Each
Party hereby represents, warrants and covenants as of the Effective Date and at all times during the Term thereafter as follows:

 

 9.1.1 Organization.

 

Such
Party (i) is a company duly organized, validly existing and in good standing under the laws of the jurisdiction where such company was
formed or incorporated, and (ii) has all necessary company power and authority to own its properties and to conduct its business, as currently
conducted.

 

 9.1.2 Authorization.

 

The
execution and delivery of this Agreement and the consummation of the transactions contemplated hereby are within the company power of
such Party, have been duly authorized by all necessary company proceedings of such Party, and this Agreement has been duly executed and
delivered by such Party.

 

 9.1.3 No Conflict.

 

The execution and
delivery of this Agreement and the consummation of the transactions contemplated herein as of the Effective Date do not, and after
the Effective Date will not: (i) conflict with or result in a breach of any provision of such Party’s organizational
documents; (ii) result in a material breach of any material agreement to which such Party is bound;
(iii) result in a violation of any judicial order to which such Party is subject; (iv) require such Party to obtain any
material approval or consent from any governmental authority or other Third Party other than those consents and approvals which have
been obtained prior to the date hereof or are expressly contemplated herein; or (v) to the knowledge of such Party, violate any
Applicable Law applicable to such Party in any material respect.

 

 9.1.4 Enforceability.

 

This
Agreement constitutes the valid and binding obligation of such Party, enforceable against such Party in accordance
with its terms, subject to bankruptcy, reorganization, insolvency and other similar laws affecting the enforcement of
creditors’ rights in general and to general principles of equity (regardless of whether considered in a proceeding in equity or an
action at law).

 

    - 14 -

     

    

 

9.2 Representations and Warranties of Healeon.

 

In
addition, Healeon hereby represents, warrants and covenants as of the Effective Date, and at all times during the Term thereafter, as
follows:

 

 9.2.1 Title to Licensed Intellectual Property.

 

Healeon
warrants that, as of the Effective Date, it solely owns or has the exclusive license with the right to sublicense to, and, except as provided
in Section 2.1, shall maintain sole ownership of or exclusive license to, all right, title, and interest in and to the Licensed
Intellectual Property within the Territory and the Field of Use, including the exclusive, absolute, irrevocable right, title and interest
thereto, free and clear of any encumbrances except as disclosed on Schedule A. To Healeon’s knowledge, there are no inventors of
Patent Rights other than those listed as inventors on patent applications filed for such Patent Rights.

 

 9.2.2 No Other Assets.

 

Other
than the Licensed Intellectual Property, neither Healeon nor any of its Affiliates (collectively, the “Healeon Parties”),
holds any ownership, license or other right in or to any Intellectual Property Rights necessary for the development manufacture, use,
sale or commercialization of any Product in the Field of Use in the Territory.

 

 9.2.3 No Infringement of Third Party Intellectual Property.

 

To Healeon’s
knowledge and after reasonable inquiry and obtaining a freedom to operate opinion from counsel of Healeon’s choice (which opinion has
been delivered to Suneva), Healeon represents and warrants that neither the Products nor their intended use within the Field of Use infringe
any Third Party’s Intellectual Property Rights.

 

 9.2.4 No Challenges to Validity or Enforceability.

 

To the knowledge
of the Healeon Parties, the title of Healeon or any other Healeon Party thereto has not been questioned in any litigation,
governmental inquiry or proceeding to which any Healeon Party is or was a Party and, to the knowledge of the Healeon Parties, no
such litigation, governmental inquiry or proceeding is threatened.

 

 9.2.5 No Known Infringements by Third Parties.

 

To
the knowledge of the Healeon Parties, there has not been and is not currently any infringement, misappropriation or unauthorized use by
any Third Party of any of the Licensed Intellectual Property.

 

 9.2.6 Preservation of Trade Secrets.

 

The
Healeon Parties have taken commercially reasonable actions necessary or appropriate to preserve the confidentiality of all trade secrets,
proprietary data and other confidential information included in the Technical Information.

 

    - 15 -

     

    

 

 9.2.7 Absence of Claims.

 

To the
knowledge of the Healeon Parties: (i) there are no suits or actions, administrative, arbitration or other proceedings, or, governmental
investigations, pending or threatened against any of the Healeon Parties with respect to the Products or any of the Licensed Intellectual
Property, (ii) no Person has notified any of the Healeon Parties in writing of any threatened claim with respect to any of the foregoing
and (iii) there is no judgment, order, injunction, decree, writ or award against any of the Healeon Parties that is not satisfied and
remains outstanding with respect to any of the foregoing.

 

 9.2.8 Compliance With Law; Regulatory Matters.

 

No
written communication has been received by any of the Healeon Parties, and to the knowledge of the Healeon Parties no regulatory enforcement
action or any related review or investigation by any Regulatory Authority or other governmental authority is pending or threatened with
respect to any alleged or actual violation by any of the Healeon Parties of any Applicable Law or other requirement of any Regulatory
Authority or other governmental authority relating to the development, clinical trials or other operations conducted by any of the Healeon
Parties with respect to any of the Licensed Intellectual Property for any Product. To the knowledge of Healeon, all Technical Information
has been developed in accordance with Applicable Law.

 

 9.2.9 Past Product Activities.

 

All
past activities by Healeon relating to the development, sales, marketing and commercialization of the Products have been conducted in
accordance with Applicable Law. Healeon is not aware of any safety issues or concerns regarding the Products. There have been no serious
adverse events related to any of the Products.

 

 9.3 Representations and Warranties of Suneva.

 

In addition, Suneva hereby represents,
warrants and covenants as of the Effective Date as follows:

 

 9.3.1 Compliance With Law; Regulatory Matters.

 

Suneva will act in
accordance with Applicable Law with respect to the sales and marketing of any Products. No written communication has been received
by Suneva, and no regulatory enforcement action or any related review, or to the knowledge of Suneva, investigation, by any
Regulatory Authority or other governmental authority is or at any time prior to the Effective Date, has been, pending
(or, to the knowledge of Suneva, is or at any time prior to the Effective Date, has been, threatened by any Regulatory
Authority or other governmental authority) with respect to any alleged or actual violation by Suneva of any Applicable Law or other
requirement of any Regulatory Authority or other governmental authority relating to the development, clinical trials and other
operations conducted by Suneva.

 

 9.3.2 No Inconsistency.

 

 Suneva
is not currently a Party to, and during the Term of this Agreement will not enter into, any agreements, oral or written, that are
inconsistent with its obligations under this Agreement.

 

 9.4 DISCLAIMER

 

EXCEPT
AS EXPRESSLY SET FORTH IN THIS ARTICLE 9, NEITHER PARTY MAKES, AND EACH HEREBY EXPRESSLY DISCLAIMS, ANY AND ALL REPRESENTATIONS
AND WARRANTIES OF ANY KIND IN CONNECTION WITH THIS AGREEMENT, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR ANY WARRANTIES ARISING FROM A COURSE OF DEALING, COURSE OF PERFORMANCE
OR USAGE OF TRADE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, NEITHER PARTY MAKES, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS, ANY
REPRESENTATION OR WARRANTY IN CONNECTION WITH THIS AGREEMENT (I)
THAT THE DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF THE PRODUCTS PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL, THAT ANY
PRODUCT WILL OBTAIN MARKETING AUTHORIZATION APPROVAL IN THE TERRITORY OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO THE PRODUCTS
WILL BE ACHIEVED OR (II) REGARDING THE EFFECTIVENESS, VALUE, SAFETY, NON-TOXICITY OR PATENTABILITY OF ANY LICENSED INTELLECTUAL PROPERTY,
PRODUCTS OR ANY RESULTS PROVIDED BY EITHER PARTY PURSUANT TO THIS AGREEMENT. NOTHING IN THIS SECTION 9.4 SHALL BE CONSTRUED TO
LIMIT OR EXCLUDE ANY REPRESENTATION OR WARRANTY EXPRESSLY MADE IN THE SUPPLY AGREEMENT.

 

ARTICLE 10

Limitation of Liability

 

 10.1 LIMITATION OF LIABILITY

 

EXCEPT WITH REGARD
TO (I) DAMAGES ARISING FROM THE
GROSS NEGLIGENCE, WILLFUL BREACH OR WILLFUL MISCONDUCT OF A PARTY, (II) ANY DUTY TO INDEMNIFY FOR DAMAGES PURSUANT TO A THIRD PARTY
CLAIM UNDER ARTICLE 13 (“INDEMNIFICATION”) AND (III) DAMAGES FOR ANY PARTY’S INFRINGEMENT OR MISAPPROPRIATION OF A
THIRD PARTY’S INTELLECTUAL PROPERTY RIGHTS OR FOR ANY PARTY’S BREACH OF THEIR CONFIDENTIALITY OBLIGATIONS HEREUNDER, TO
THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW IN NO EVENT SHALL EITHER PARTY OR ANY OF THEIR RESPECTIVE AFFILIATES BE LIABLE
FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR
CONSEQUENTIAL DAMAGES OR FOR ANY LOSS OF PROFITS, REVENUE OR INTEREST, ARISING FROM OR IN CONNECTION WITH THIS AGREEMENT, WHETHER
BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY AND IRRESPECTIVE OF WHETHER SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF ANY
SUCH LOSS OR DAMAGE.

 

    - 16 -

     

    

 

ARTICLE 11

Indemnification; Insurance

 

11.l Mutual Indemnities; Indemnity
Procedures

 

11.1.1
Indemnity by Suneva.

 

Suneva
shall defend, indemnify and hold harmless Healeon and its Affiliates, and their respective members, managers, directors, employees, officers
and agents (collectively, the “Healeon Indemnitees”) from and against any and all liability, demands, damages, fines, costs
and expenses (including, without limitation, reasonable legal fees and expenses) and losses (including, without limitation, with respect
to death, personal injury, illness or property damage) incurred by or awarded to Third Parties (collectively, “Losses”) which
are required to be paid by any Healeon Indemnitee in connection with any Third Party claim, complaint, demand, suit, action, investigation
or proceeding (collectively, “Third Party Claims”) to the extent arising from any allegations: (i) which if true would constitute
a breach by Suneva of any representation, warranty, covenant or other provision set forth in this Agreement, (ii) which if true would
constitute negligence or willful misconduct of any of the Suneva Indemnitees (as defined below) or Suneva’s Sublicensees. or (iii) that
arise or result from the development, commercialization, manufacture, use, marketing, offer for sale, sale, import, handling, storage,
distribution or other disposition of Products by Suneva or its Sublicensees. The foregoing indemnity obligation shall not apply to the
extent that such Losses result from or relate to either (A) negligence or willful misconduct of a Healeon Indemnitee (B) the breach of
this Agreement by a Healeon Indemnitee (C) any dispute or conflict between a Healeon Indemnitee and a Third Party in existence prior to
the Effective Date or (D) any allegation of infringement of any Intellectual Property Rights by a Third Party.

 

 11.1.2 Indemnity by Healeon.

 

Healeon
shall defend, indemnify and hold harmless Suneva and its Affiliates, and their respective members, managers, directors, employees,
officers and agents (collectively, the “Suneva lndemnitees”) from and against any and all Losses which are
required to be paid by any Suneva Indemnitee in connection with any Third Party Claim against a Suneva Indemnitee to the extent
arising from any allegations: (i) which if true would constitute a breach by Healeon of any representation, warranty, covenant or
other provision set forth in this Agreement, (ii) which if true would constitute negligence or willful misconduct of any of the
Healeon Indemnitees or (iii) that arise or result from the development, commercialization, manufacture, use, marketing, offer for
sale, sale, import, handling, storage, distribution or other
disposition of Products by a Healeon Indemnitee prior to the Effective Date.
The foregoing indemnity obligation shall not apply to the extent that such Losses result from or relate to either (A)
negligence or willful misconduct of a Suneva Indemnitee or (B) the breach of this Agreement by a Suneva Indemnitee or (C) any
dispute between a Suneva Indemnitee and a Third Party in existence prior to the Effective Date.

 

 11.1.3 Indemnity Procedures.

 

In the event that either
Party intends to seek indemnification for any Third Party Claim under Sections 11.1.1 or 11.1.2, such Party (the “Indemnified
Party”) shall inform the other Party (the “Indemnifying Party”) of the Third Party Claim promptly after
receiving notice of the Third Party Claim; provided, however,
that any failure to provide such notice shall not relieve the Indemnifying Party of its obligations under this Article 12
except to the extent the Indemnifying Party is materially prejudiced by such failure. The Indemnified Party shall permit the Indemnifying
Party to direct and control the defense of such Third Party Claim and shall provide such reasonable assistance as is reasonably requested
by the Indemnifying Party (at the Indemnifying Party’s cost) in the defense
of the Third Party Claim. In any such proceeding, the Indemnified Party, at its sole expense, shall have the right to retain its own
counsel. Nothing in this Article 12 or in Article 8 shall permit a Party to make any admission on behalf of the other Party,
or to settle or dispose of any claim or litigation which would impose any financial obligations on the other Party, or subject the other
Party to an injunction or equitable relief, without the prior written consent of the other Party, such consent not to be unreasonably
withheld or delayed.

 

11.2 Insurance

 

During
the Term of this Agreement and for five (5) years thereafter, each Party shall maintain insurance with respect to its activities under
this Agreement as is normal and customary in the industry generally for parties similarly situated. Each Party shall, upon request of
the other Party, provide the requesting Party with a copy of the foregoing policies of insurance, along with any amendments and revisions
thereto.

 

    - 17 -

     

    

 

ARTICLE 12

Confidentiality

 

 12.1 Confidentiality and Non-Use

 

 12.1.1 Obligations

 

Any information
relating to a Party’s business, technologies or finances, Intellectual Property Rights (and, in the case of Healeon, any
Technical Information) disclosed to the other Party under this Agreement that is marked or otherwise identified as proprietary or
confidential at the time of disclosure or that is of such a nature that a reasonable person would understand such information to be
proprietary or confidential collectively constitutes that Party’s “Confidential
Information.” Neither Party will use the Confidential Information of the other Party for any purpose unrelated to
the exercise of its rights or fulfillment of its obligations under this Agreement, and each Party will hold such Confidential
Information in confidence during the Term and for a period of ten (10) years after the termination or expiration date of this
Agreement (except that Confidential Information identified by a Party as a trade secret shall be held in confidence for
as long as such information remains a trade secret). Each Party shall exercise with respect to the Confidential Information of the
other Party the same degree of care as the Party exercises with respect to its own confidential or proprietary information of a
similar nature, but in no event less than reasonable care, and shall not disclose it or permit its disclosure to any Third Party,
other than: (i) to its Affiliates, and those of its and its Affiliates’ respective employees, Sublicensees, consultants,
contractors, accountants, attorneys, advisors and agents, as well as to any potential acquirers, investors or lenders and their
respective advisors, in each of the foregoing cases who have a need to know and who are bound by materially similar obligations of
confidentiality and non-use as those of this Agreement and (ii) by or on behalf of Suneva to any applicable Regulatory Authority in
connection with the regulatory approval process for any Product. Each Party shall be responsible for any breaches of confidentiality
by any of its Affiliates, or its Affiliates’ respective employees, Sublicensees, consultants, contractors, accountants,
attorneys, advisors or agents, or any potential acquirers, investors or lenders or their respective advisors.

 

 12.1.2 Exceptions

 

However, such undertaking
of confidentiality (as described in Section 12.1.1) shall not apply to any information
or data which:

 

		(i)	the receiving Party lawfully receives without obligation
of confidentiality at any time from a Third Party lawfully in possession of same and having the right to disclose same;

 

		(ii)	is, as of the Effective Date, in the public domain, or subsequently
enters the public domain through no fault of the receiving Party;

 

		(iii)	is independently developed by the receiving Party as demonstrated
by written evidence without reference to or benefit of information disclosed to the receiving Party by the disclosing Party; or

 

		(iv)	is publically disclosed pursuant to the prior, written approval
of the disclosing Party.

 

 12.1.3 Required Disclosure

 

If a Party is required
to disclose any Confidential Information of the other Party pursuant to Applicable Law or legal process, the first Party shall (i) give
prior, written notice of such required disclosure to the other Party, to the extent reasonably practicable, (ii) give reasonable assistance
to the other Party, if requested thereby, seeking confidential or protective treatment thereof, and (iii) only disclose such Confidential
Information to the extent required by such Applicable Law or legal process based on the advice of such Party’s legal counsel; provided,
however, that the foregoing requirement shall not apply with respect to any
disclosures by Suneva to any applicable Regulatory Authority in connection with the regulatory approval process for any Product.

 

    - 18 -

     

    

 

ARTICLE 13

General
Provisions

13.1
Relationship of the Parties

Nothing herein shall
be deemed to establish a relationship of principal and agent between Healeon and Suneva, nor any of their agents or employees for any
purpose whatsoever. This Agreement shall not be construed as creating a partnership between Healeon and Suneva, or as creating any other
form of legal association or arrangement, which would impose liability upon one Party for the act or failure to act of the other Party.
No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement in any manner
whatsoever, or to create or impose any contractual or other liability on the other Party without said Party’s approval. For all purposes,
the parties’ legal relationship under this Agreement to each other shall be that of independent contractors.

 

 13.2 Assignment

 

This Agreement and the rights
and duties appertaining hereto may not be assigned or otherwise transferred by either Party without first obtaining the written consent
of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, if a Party
is acquired by a Third Party, or if substantially all of the assets of a Party or the business to which this Agreement relates are acquired
by a Third Party, then the Party may assign its rights and obligations to said acquiring Third Party without the consent of the other
Party.

 

 13.3 Binding Nature and Inurement

 

This
Agreement is binding upon and inures to the benefit of the parties and their respective permitted successors and assigns. For the avoidance
of doubt, a Change of Control will not terminate and is not grounds for termination of this License Agreement or the Supply Agreement.

 

 13.4 Entire Agreement; Amendment

 

The
parties hereto acknowledge that this Agreement (including the Schedules hereto and the Supply Agreement) sets forth the entire agreement
and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change or modification except
by the execution of a written instrument signed by the parties hereto, and shall supersede all previous communications, representations
or understandings, either oral or written, between the parties relating to the subject matter hereof, including the Original Agreement.
No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the parties hereto unless reduced to writing
and signed by the respective authorized officers of the parties.

 

 13.5 Further Assurances

 

From
time to time during the Term, at the reasonable request of either Party, the other Party shall execute and deliver such documents and
take such other action as the requesting Party may reasonably request to consummate more effectively the transactions contemplated hereby.

 

13.6
Governing Law

 

This
Agreement, and any disputes arising directly or indirectly from this Agreement, shall be governed by and construed and enforced in accordance
with the laws of the state of California, without regard to its conflict-of-laws rules. The parties agree that any claims arising under
this Agreement shall be exclusively venued in the state and federal courts located in San Diego County, California. Each Party hereby
irrevocably submits to the exclusive jurisdiction of such courts for any such claims, and waives any objections to the laying of venue
in such courts. Unless expressly provided otherwise, each right and remedy in this Agreement is in addition to any other right or remedy,
at law or in equity, and the exercise of one right or remedy will not be deemed a waiver of any other right or remedy.

 

    - 19 -

     

    

 

 13.7 Public Announcements

 

Except
as may be expressly permitted under Article 13 or mandated by Applicable Laws or the rules of any stock exchange, neither Party
will make any public announcement of any information regarding this Agreement without the prior written consent of the other Party. Once
any statement is approved for disclosure by the parties, either Party may make a subsequent public disclosure containing the same information
disclosed in such prior public announcement without further approval of the other Party.

 

13.8 Notices

 

All
notices, claims, demands and other communications hereunder shall be in writing and shall be deemed given if delivered personally, one
(1) business day after being sent by major overnight courier, or four (4) business days after being mailed by registered or certified
mail (postage prepaid, return receipt requested) to each Party at its respective address set forth below (or at such other address as
any Party hereto shall hereafter specify by notice in writing to the other parties hereto).

 

If
to Healeon:

 

1111 Rancho Conejo Blvd #204

 

Newbury Park, CA 91320

Attn: Chief Executive Officer

 

If
to Suneva:

 

5870 Pacific Center Blvd

San Diego, CA 92121

Attn: Chief Executive Officer

 

 13.9 Payment of Own Fees and Expenses

 

Each of Suneva and Healeon
shall be responsible for their own expenses relating to the preparation and consummation of this Agreement and, except as specified herein,
the agreements and transactions contemplated hereby.

 

13.10 Severability

 

The provisions of this
Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable
under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of
the remaining provisions hereof.

 

 13.11 Waiver

 

The failure of either
Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a
waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. Any waiver of
any rights or failure to act in a specific instance must be, with respect any waiver, provided in writing to be effective and
relates only to that instance and is not an agreement to waive any rights or fail to act in any other instance.

 

 13.12 Headings

 

The
headings of the several articles are inserted for convenience of reference only and are not intended to be a part of or to affect the
meaning or interpretation of this Agreement. Unless the context of this Agreement otherwise requires, the use of the terms “include”,
“includes” and “including” are not limiting.

 

 13.13 Counterparts; Facsimile

 

This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. This Agreement may be signed and delivered to the other Party by facsimile signature; such transmission will
be deemed a valid signature.

 

[Signature page follows]

 

    - 20 -

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this License Agreement by their duly authorized representatives,

 

	SUNEVA MEDICAL, INC.	HEALEON MEDICAL, INC.
	 	 
	 	HEALEON MEDICAL LTD.
	 	 
	By:	/s/ Preston Romm	 	By:	/s/ Jeff Greiner
	Name: 	Preston Romm 	 	Name: 	Jeff Greiner
	Title: 	President & CEO	 	Title: 	CEO

 

 

- 21 -Exhibit 10.34

 

FIRST AMENDMENT TO

LICENSE AGREEMENT

 

This FIRST AMENDMENT TO LICENSE AGREEMENT (the
“Amendment”) is entered into as of March 20, 2020 (the “Amendment Date”), by and among Suneva
Medical, Inc., a Dela ware corporation (“Suneva”) and Healeon Medical, Inc., a California corporation (“Healeon”).
Capitalized terms used in this Amendment and not otherwise defined in this Amendment have the respective meanings ascribed
to them in the Prior Agreement (as defined below).

 

RECITALS

 

A. Suneva and Healeon previously
entered into that certain License Agreement on the Ef fective Date (the “Prior Agreement”); and

 

B. Hcalcon
did not obtain U.S. Regulatory Approval for certain Products on or before December 31, 20 I 9, and subsequently owes Suncva a refund
amount of $300,000 pursuant to the tem1s of the Prior Agreement (the “Original Refund Amount”).

 

C. The
Parties wish to offset certain amounts owed to Healcon by Suneva (in the aggre gate amount of $165,920.50, as further itemized on Exhibit
A hereto) against the Original Re fund Amount, leaving Healeon with an obligation to Suneva in the amount of $134,079.50 (the “Revised
Refund Amount”).

 

D. The
Parties wish to provide for further offsets to the Revised Refund Amount through subsequent amendments to Exhibit A, and such exhibit
will be automatically amended to include any valid, undisputed, invoice issued by Heal eon to Suncva of which both parties decide to apply
to the Revised Refund Amount until the amount of all offsets set forth in Exhibit A is $300,000.

 

E. The
Original Refund Amount was to be paid ,by Healeon on or before March 20, 2020, but the Parties wish to extend the payment date for the
Revised Refund Amount to June 30, 2021.

 

    

     

    

 

AGREEMENT

 

Now THEREFORE, in consideration of the premises
set forth above and the mutual covenants and agreements set forth herein and for good and va uable consideration, the receipt and adequacy
of which are hereby acknowledged, the parties to this Amendment agree as follows:

  

1. Amendment
to Financial Terms. The last sentence of Section 6.1 of the Prior Agreement is hereby removed in its entirety and replaced with the
following language:

 

“Healeon shall pay Suneva a license
payment refund in the amount of $134,079.50 (the “Refund Amount”), with such Refund Amount to be paid on or before
June 30, 2021 (the “Refund Due Date”). The Parties agree that in the event Healeon issues additional, undisputed,
invoices to Suncva after March 20, 2020, that upon agreement by both Parties, the amounts of such invoices will be added to Exhibit
A of that certain First Amendment to License Agreement between the Parties dated March 20, 2020, and the Refund Amount will be
automatically reduced by the amount of such invoice. The offset provision described in the previous sentence can be applied until
the Refund Amount is $0. In the event that any part of the Refund Amount remains outstanding as of the Refund Due Date, Healeon will
pay such amount to Suneva in cash or via wire transfer. Healcon shall pay all collection costs, including reasonable attorneys’
fees (including in-house counsel), incurred by Suneva in collecting the Refund Amount or in enforcing the provisions of this
Agreement, whether or not Suneva files a suit. Last, Healeon agrees that as of March 20, 2020, the price per unit that it will
charge Suneva for the PRP syringe “Single Dual Syringe PRP Kit” will be $23.00 until the Refund Amount is $0 due to
offsets or paid in full by Healcon.”

 

2. Continuation
of Terms. Except as amended hereby, all other terms and condi- tions of the Prior Agreement will be unaffected by this Amendment and
remain in full force and effect.

  

3.
Miscellaneous.

 

3.1. This
Amendment, together with the Prior Agreement, constitutes the entire agreement among the parties and supersedes all prior agreements and
understandings relating to the subject matter of this Amendment.

 

3.2. Any
dispute arising under this Amendment shall be subject to the dispute resolution process applicable to the Prior Agreement.

 

3.3. This
Amendment will be governed by the governing law applicable to the Prior Agreement.

  

3.4. This
Amendment may be executed and delivered by two or more counter- parts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Any signature page delivered by facsimile or e-mail transmission of images in Adobe PDF
or similar format shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms
hereof or any amendment thereto.

  

[SIGNATURE PAGE FOLLOWS]

 

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]